Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | NSCLC | Research

Quantification of preexisting lung ground glass opacities on CT for predicting checkpoint inhibitor pneumonitis in advanced non-small cell lung cancer patients

Authors: Xinyue Wang, Jinkun Zhao, Ting Mei, Wenting Liu, Xiuqiong Chen, Jingya Wang, Richeng Jiang, Zhaoxiang Ye, Dingzhi Huang

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Background

Immune checkpoint inhibitors (ICIs) can lead to life-threatening pneumonitis, and pre-existing interstitial lung abnormalities (ILAs) are a risk factor for checkpoint inhibitor pneumonitis (CIP). However, the subjective assessment of ILA and the lack of standardized methods restrict its clinical utility as a predictive factor. This study aims to identify non-small cell lung cancer (NSCLC) patients at high risk of CIP using quantitative imaging.

Methods

This cohort study involved 206 cases in the training set and 111 cases in the validation set. It included locally advanced or metastatic NSCLC patients who underwent ICI therapy. A deep learning algorithm labeled the interstitial lesions and computed their volume. Two predictive models were developed to predict the probability of grade ≥ 2 CIP or severe CIP (grade ≥ 3). Cox proportional hazard models were employed to analyze predictors of progression-free survival (PFS).

Results

In a training cohort of 206 patients, 21.4% experienced CIP. Two models were developed to predict the probability of CIP based on different predictors. Model 1 utilized age, histology, and preexisting ground glass opacity (GGO) percentage of the whole lung to predict grade ≥ 2 CIP, while Model 2 used histology and GGO percentage in the right lower lung to predict grade ≥ 3 CIP. These models were validated, and their accuracy was assessed. In another exploratory analysis, the presence of GGOs involving more than one lobe on pretreatment CT scans was identified as a risk factor for progression-free survival.

Conclusions

The assessment of GGO volume and distribution on pre-treatment CT scans could assist in monitoring and manage the risk of CIP in NSCLC patients receiving ICI therapy.

Clinical relevance statement

This study’s quantitative imaging and computational analysis can help identify NSCLC patients at high risk of CIP, allowing for better risk management and potentially improved outcomes in those receivingICI treatment.
Appendix
Available only for authorised users
Literature
1.
Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, et al. Nivolumab versus Docetaxel in Advanced squamous-cell non-small-cell Lung Cancer. N Engl J Med. 2015;373(2):123–35.PubMedPubMedCentralCrossRef
2.
Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-small-cell Lung Cancer. N Engl J Med. 2015;373(17):1627–39.PubMedPubMedCentralCrossRef
3.
Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, et al. Pembrolizumab versus Docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–50.PubMedCrossRef
4.
Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive non-small-cell Lung Cancer. N Engl J Med. 2016;375(19):1823–33.PubMedCrossRef
5.
Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, Park K, Smith D, Artal-Cortes A, Lewanski C, et al. Atezolizumab versus Docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387(10030):1837–46.PubMedCrossRef
6.
Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, et al. Atezolizumab versus Docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255–65.PubMedCrossRef
7.
Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events Associated with Immune Checkpoint Blockade. N Engl J Med. 2018;378(2):158–68.PubMedCrossRef
8.
Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with Advanced Cancer: a systematic review and Meta-analysis. JAMA Oncol. 2016;2(12):1607–16.PubMedCrossRef
9.
Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, Shabafrouz K, Ribi C, Cairoli A, Guex-Crosier Y, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16(9):563–80.PubMedCrossRef
10.
Khunger M, Rakshit S, Pasupuleti V, Hernandez AV, Mazzone P, Stevenson J, Pennell NA, Velcheti V. Incidence of Pneumonitis with Use of programmed death 1 and programmed death-ligand 1 inhibitors in Non-small Cell Lung Cancer: a systematic review and Meta-analysis of trials. Chest. 2017;152(2):271–81.PubMedCrossRef
11.
Suresh K, Voong KR, Shankar B, Forde PM, Ettinger DS, Marrone KA, Kelly RJ, Hann CL, Levy B, Feliciano JL, et al. Pneumonitis in Non-small Cell Lung Cancer patients receiving Immune Checkpoint Immunotherapy: incidence and risk factors. J Thorac Oncol. 2018;13(12):1930–9.PubMedCrossRef
12.
Fukihara J, Sakamoto K, Koyama J, Ito T, Iwano S, Morise M, Ogawa M, Kondoh Y, Kimura T, Hashimoto N, et al. Prognostic impact and risk factors of Immune-related pneumonitis in patients with non-small-cell Lung Cancer who received programmed death 1 inhibitors. Clin Lung Cancer. 2019;20(6):442–450e444.PubMedCrossRef
13.
Suresh K, Psoter KJ, Voong KR, Shankar B, Forde PM, Ettinger DS, Marrone KA, Kelly RJ, Hann CL, Levy B, et al. Impact of checkpoint inhibitor pneumonitis on Survival in NSCLC patients receiving Immune Checkpoint Immunotherapy. J Thorac Oncol. 2019;14(3):494–502.PubMedCrossRef
14.
Cho JY, Kim J, Lee JS, Kim YJ, Kim SH, Lee YJ, Cho YJ, Yoon HI, Lee JH, Lee CT, et al. Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer. Lung Cancer. 2018;125:150–6.PubMedCrossRef
15.
Delaunay M, Cadranel J, Lusque A, Meyer N, Gounant V, Moro-Sibilot D, Michot JM, Raimbourg J, Girard N, Guisier F et al. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. Eur Respir J 2017;50(2).
16.
Owen DH, Wei L, Bertino EM, Edd T, Villalona-Calero MA, He K, Shields PG, Carbone DP, Otterson GA. Incidence, risk factors, and Effect on Survival of Immune-related adverse events in patients with non-small-cell Lung Cancer. Clin Lung Cancer. 2018;19(6):e893–e900.PubMedPubMedCentralCrossRef
17.
Naidoo J, Wang X, Woo KM, Iyriboz T, Halpenny D, Cunningham J, Chaft JE, Segal NH, Callahan MK, Lesokhin AM, et al. Pneumonitis in patients treated with Anti-programmed Death-1/Programmed death Ligand 1 therapy. J Clin Oncol. 2017;35(7):709–17.PubMedCrossRef
18.
Yamaguchi T, Shimizu J, Hasegawa T, Horio Y, Inaba Y, Yatabe Y, Hida T. Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: a retrospective analysis. Lung Cancer. 2018;125:212–7.PubMedCrossRef
19.
Suzuki Y, Karayama M, Uto T, Fujii M, Matsui T, Asada K, Kusagaya H, Kato M, Matsuda H, Matsuura S, et al. Assessment of Immune-related interstitial lung disease in patients with NSCLC treated with Immune Checkpoint inhibitors: a Multicenter prospective study. J Thorac Oncol. 2020;15(8):1317–27.PubMedCrossRef
20.
Kanai O, Kim YH, Demura Y, Kanai M, Ito T, Fujita K, Yoshida H, Akai M, Mio T, Hirai T. Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease. Thorac Cancer. 2018;9(7):847–55.PubMedPubMedCentralCrossRef
21.
Shibaki R, Murakami S, Matsumoto Y, Yoshida T, Goto Y, Kanda S, Horinouchi H, Fujiwara Y, Yamamoto N, Kusumoto M, et al. Association of immune-related pneumonitis with the presence of preexisting interstitial lung disease in patients with non-small lung cancer receiving anti-programmed cell death 1 antibody. Cancer Immunol Immunother. 2020;69(1):15–22.PubMedCrossRef
22.
Yamaguchi T, Shimizu J, Hasegawa T, Horio Y, Inaba Y, Hanai N, Muro K, Hida T. Pre-existing interstitial lung disease is associated with onset of nivolumab-induced pneumonitis in patients with solid tumors: a retrospective analysis. BMC Cancer. 2021;21(1):924.PubMedPubMedCentralCrossRef
23.
Zhang M, Fan Y, Nie L, Wang G, Sun K, Cheng Y. Clinical outcomes of Immune checkpoint inhibitor therapy in patients with Advanced Non-small Cell Lung Cancer and Preexisting interstitial lung diseases: a systematic review and Meta-analysis. Chest. 2022;161(6):1675–86.PubMedCrossRef
24.
Hatabu H, Hunninghake GM, Richeldi L, Brown KK, Wells AU, Remy-Jardin M, Verschakelen J, Nicholson AG, Beasley MB, Christiani DC, et al. Interstitial lung abnormalities detected incidentally on CT: a position paper from the Fleischner Society. Lancet Respir Med. 2020;8(7):726–37.PubMedPubMedCentralCrossRef
25.
Nakanishi Y, Masuda T, Yamaguchi K, Sakamoto S, Horimasu Y, Nakashima T, Miyamoto S, Tsutani Y, Iwamoto H, Fujitaka K, et al. Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer. Respir Investig. 2019;57(5):451–9.PubMedCrossRef
26.
Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ. 2015;350:g7594.PubMedCrossRef
27.
Jin GY, Lynch D, Chawla A, Garg K, Tammemagi MC, Sahin H, Misumi S, Kwon KS. Interstitial lung abnormalities in a CT lung cancer screening population: prevalence and progression rate. Radiology. 2013;268(2):563–71.PubMedPubMedCentralCrossRef
28.
Li Z, Zhang S, Zhang J, Huang K, Wang Y, Yu Y. MVP-Net: multi-view FPN with position-aware attention for deep universal lesion detection. In: International Conference on Medical Image Computing and Computer-Assisted Intervention: 2019: Springer; 2019:13–21.
29.
Travis WD, Costabel U, Hansell DM, King TE Jr., Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AU, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188(6):733–48.PubMedPubMedCentralCrossRef
30.
Nishino M, Ramaiya NH, Awad MM, Sholl LM, Maattala JA, Taibi M, Hatabu H, Ott PA, Armand PF, Hodi FS. PD-1 inhibitor-related pneumonitis in Advanced Cancer patients: radiographic patterns and clinical course. Clin Cancer Res. 2016;22(24):6051–60.PubMedPubMedCentralCrossRef
31.
Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, Budde LE, Costa L, Davies M, Dunnington D, et al. NCCN guidelines insights: management of immunotherapy-related toxicities, Version 1.2020. J Natl Compr Canc Netw. 2020;18(3):230–41.PubMedCrossRef
32.
Nishino M, Cardarella S, Dahlberg SE, Araki T, Lydon C, Jackman DM, Rabin MS, Hatabu H, Johnson BE. Interstitial lung abnormalities in treatment-naive advanced non-small-cell lung cancer patients are associated with shorter survival. Eur J Radiol. 2015;84(5):998–1004.PubMedPubMedCentralCrossRef
33.
Yamaguchi S, Ohguri T, Ide S, Aoki T, Imada H, Yahara K, Narisada H, Korogi Y. Stereotactic body radiotherapy for lung tumors in patients with subclinical interstitial lung disease: the potential risk of extensive radiation pneumonitis. Lung Cancer. 2013;82(2):260–5.PubMedCrossRef
34.
Higo H, Kubo T, Makimoto S, Makimoto G, Ihara H, Masaoka Y, Ninomiya T, Ichihara E, Ohashi K, Sato A, et al. Chemoradiotherapy for locally advanced lung cancer patients with interstitial lung abnormalities. Jpn J Clin Oncol. 2019;49(5):458–64.PubMedCrossRef
35.
Kahn CE Jr. From images to actions: opportunities for Artificial Intelligence in Radiology. Radiology. 2017;285(3):719–20.PubMedCrossRef
36.
Choy G, Khalilzadeh O, Michalski M, Do S, Samir AE, Pianykh OS, Geis JR, Pandharipande PV, Brink JA, Dreyer KJ. Current applications and future impact of machine learning in Radiology. Radiology. 2018;288(2):318–28.PubMedCrossRef
37.
Iwasawa T, Okudela K, Takemura T, Fukuda T, Matsushita S, Baba T, Ogura T, Tajiri M, Yoshizawa A. Computer-aided quantification of pulmonary fibrosis in patients with Lung Cancer: relationship to Disease-free survival. Radiology. 2019;292(2):489–98.PubMedCrossRef
38.
Jacob J, Bartholmai BJ, Rajagopalan S, Kokosi M, Egashira R, Brun AL, Nair A, Walsh SLF, Karwoski R, Wells AU. Serial automated quantitative CT analysis in idiopathic pulmonary fibrosis: functional correlations and comparison with changes in visual CT scores. Eur Radiol. 2018;28(3):1318–27.PubMedCrossRef
39.
Nishiyama N, Honda T, Sema M, Kawahara T, Jin Y, Natsume I, Chiaki T, Yamashita T, Tsukada Y, Taki R, et al. The utility of ground-glass attenuation score for anticancer treatment-related acute exacerbation of interstitial lung disease among lung cancer patients with interstitial lung disease. Int J Clin Oncol. 2020;25(2):282–91.PubMedCrossRef
40.
Shimoji K, Masuda T, Yamaguchi K, Sakamoto S, Horimasu Y, Nakashima T, Miyamoto S, Iwamoto H, Fujitaka K, Hamada H, et al. Association of Preexisting Interstitial Lung Abnormalities with Immune Checkpoint inhibitor-Induced interstitial lung disease among patients with Nonlung Cancers. JAMA Netw Open. 2020;3(11):e2022906.PubMedPubMedCentralCrossRef
41.
Naidoo J, Cottrell TR, Lipson EJ, Forde PM, Illei PB, Yarmus LB, Voong KR, Feller-Kopman D, Lee H, Riemer J et al. Chronic immune checkpoint inhibitor pneumonitis. J Immunother Cancer 2020, 8(1).
42.
Suresh K, Naidoo J, Zhong Q, Xiong Y, Mammen J, de Flores MV, Cappelli L, Balaji A, Palmer T, Forde PM, et al. The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis. J Clin Invest. 2019;129(10):4305–15.PubMedPubMedCentralCrossRef
43.
Suzuki K, Yanagihara T, Matsumoto K, Kusaba H, Yamauchi T, Ikematsu Y, Tanaka K, Otsubo K, Inoue H, Yoneshima Y, et al. Immune-checkpoint profiles for T cells in bronchoalveolar lavage fluid of patients with immune-checkpoint inhibitor-related interstitial lung disease. Int Immunol. 2020;32(8):547–57.PubMedCrossRef
44.
Andruska N, Mahapatra L, Hebbard C, Patel P, Paul V. Severe pneumonitis refractory to steroids following anti-PD-1 immunotherapy. BMJ Case Rep. 2018, 2018.
45.
Naqash AR, Yang LV, Sanderlin EJ, Atwell DC, Walker PR. Interleukin-6 as one of the potential mediators of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint blockade: evidence from a case report. Acta Oncol. 2018;57(5):705–8.PubMedCrossRef
46.
Utsumi H, Araya J, Okuda K, Watanabe J, Takekoshi D, Fujita Y, Hashimoto M, Wakui H, Minagawa S, Numata T, et al. Successful treatment of steroid-refractory immune checkpoint inhibitor-related pneumonitis with triple combination therapy: a case report. Cancer Immunol Immunother. 2020;69(10):2033–9.PubMedCrossRef
47.
Tasaka Y, Honda T, Nishiyama N, Tsutsui T, Saito H, Watabe H, Shimaya K, Mochizuki A, Tsuyuki S, Kawahara T, et al. Non-inferior clinical outcomes of immune checkpoint inhibitors in non-small cell lung cancer patients with interstitial lung disease. Lung Cancer. 2021;155:120–6.PubMedCrossRef
48.
Yu Q, Wang Y, Huang S, Liu S, Zhou Z, Zhang S, Zhao Z, Yu Y, Yang Y, Ju S. Multicenter cohort study demonstrates more consolidation in upper lungs on initial CT increases the risk of adverse clinical outcome in COVID-19 patients. Theranostics. 2020;10(12):5641–8.PubMedPubMedCentralCrossRef
49.
Wang YC, Luo H, Liu S, Huang S, Zhou Z, Yu Q, Zhang S, Zhao Z, Yu Y, Yang Y, et al. Dynamic evolution of COVID-19 on chest computed tomography: experience from Jiangsu Province of China. Eur Radiol. 2020;30(11):6194–203.PubMedPubMedCentralCrossRef
50.
Ni Q, Sun ZY, Qi L, Chen W, Yang Y, Wang L, Zhang X, Yang L, Fang Y, Xing Z, et al. A deep learning approach to characterize 2019 coronavirus disease (COVID-19) pneumonia in chest CT images. Eur Radiol. 2020;30(12):6517–27.PubMedPubMedCentralCrossRef
Metadata
Title
Quantification of preexisting lung ground glass opacities on CT for predicting checkpoint inhibitor pneumonitis in advanced non-small cell lung cancer patients
Authors
Xinyue Wang
Jinkun Zhao
Ting Mei
Wenting Liu
Xiuqiong Chen
Jingya Wang
Richeng Jiang
Zhaoxiang Ye
Dingzhi Huang
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-12008-z

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue

Research

Population-based BRCA germline mutation screening in the Han Chinese identifies individuals at risk of BRCA mutation-related cancer: experience from a clinical diagnostic center from greater Shanghai area

Research

Translation and validation of a simplified Chinese version of the psychosocial assessment tool

Research

Transgelin-2, a novel cancer stem cell-related biomarker, is a diagnostic and therapeutic target for biliary tract cancer

Research

Cost-effectiveness of immunotherapies for advanced squamous non-small cell lung cancer: a systematic review

Research

Hsa_circ_0005397 promotes hepatocellular carcinoma progression through EIF4A3

Retraction Note

Retraction Note: Knockdown long non-coding RNA ANRIL inhibits proliferation, migration and invasion of HepG2 cells by down-regulation of miR-191
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits